Table 1.
Characteristics of subjects enrolled in study
| Subject | Group | Autoantibody1 | Gender | Age2 | DRB1 haplotype |
|---|---|---|---|---|---|
| 5574 | At-risk | GAD, IA-2 | M | 13 | *0401/*0301 |
| 6211 | At-risk | IA-2 | F | 15 | *0401/*0701 |
| 6827 | At-risk | IAA | M | 16 | *0401/*1502 |
| 6212 | At-risk | GAD, IA-2 | F | 17 | *0404/*0405 |
| 6899 | At-risk | GAD | F | 17 | *0401/*0403 |
| 0909 | At-risk | GAD, IA-2 | M | 17 | *0401/*1301 |
| 2824 | At-risk | GAD, IA-2 | M | 18 | *0401/*0301 |
| 5571 | At-risk | GAD, IA-2 | F | 19 | *0401/*0301 |
| 5725 | At-risk | GAD | F | 22 | *0401/*0401 |
| 4845 | At-risk | GAD | F | 39 | *0401/*0301 |
| 0901 | At-risk | GAD, IA-2 | F | 40 | *0401/*0301 |
| 8617 | At-risk | GAD, IA-2 | M | 45 | *0401/*0301 |
| 7625 | Diabetes (3 mo. post-diag.) | GAD, IA-2 | F | 14 | *0401/*0301 |
| 6754 | Diabetes (11 mo. post-diag.) | GAD, IA-2, IAA | M | 15 | *0401/*1302 |
| 0912 | Diabetes (16 mo. post-diag.) | GAD, IA-2 | M | 15 | *0401/*0901 |
| 0904 | Diabetes (38 mo. post-diag.) | GAD, IA-2 | M | 16 | *0401/*0101 |
| 5573 | Diabetes (1 mo. post-diag.) | GAD, IA-2, IAA | F | 18 | *0401/*0801 |
| 7553 | Diabetes (1 mo. post-diag.) | IA-2 | M | 19 | *0401/*0101 |
| 7581 | Diabetes (1 mo. post-diag.) | GAD, IA-2 | M | 24 | *0401/*1101 |
| 0908 | Diabetes (14 mo. post-diag.) | GAD, IA-2 | M | 24 | *0401/*0401 |
| 0907 | Diabetes (45 mo. post-diag.) | GAD, IA-2 | M | 28 | *0401/*1302 |
| 7472 | First-degree relative | Negative | F | 26 | *0401/*0301 |
| 6660 | First-degree relative | Negative | F | n/d | *0401/*0301 |
| 7052 | First-degree relative | Negative | F | n/d | *0401/*1302 |
| 0913 | First-degree relative | Negative | M | 57 | *0401/*1501 |
1
presence of GAD 65, IA-2, or insulin autoantibodies at time of initial sample collection;
2
age in years at time of initial sample collection; n/d: not determined